Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT06617897

Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

Led by CSL Behring · Updated on 2026-03-11

90

Participants Needed

1

Research Sites

160 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is a phase 3, prospective, single center, randomized, open label, controlled, parallel arm, interventional study to investigate the efficacy and safety of CSL511, in participants undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP) with predicted intraoperative blood loss of greater than or equal to (\>=) 2 liter (L). Eligible participants will be randomized in a 1:1 ratio to 1 of 2 treatment arms, to receive CSL511 or cryoprecipitate.

CONDITIONS

Official Title

Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • • Aged >= 18 years at the time of providing written informed consent.
  • • Diagnosis of PMP requiring CRS with HIPEC.
  • • Bleeding risk: Predicted intraoperative blood loss of >=2L, assessed within 60 and 100 mins after start of study surgery (assessment made before 2 L of blood is lost)
Not Eligible

You will not qualify if you...

  • • Confirmed or suspected congenital or acquired coagulation disorder or a prothrombotic disorder
  • • Myocardial infarction, acute coronary syndrome, or stroke within 2 months before study surgery.
  • • Known history of chronic hepatitis.
  • • Clopidogrel or ticagrelor administration within 5 days before study surgery.
  • • Prasugrel administration within 7 days before study surgery.
  • • Oral factor Xa inhibitor administration within 2 days before study surgery.
  • • Glycoprotein IIb / IIIa antagonist administration within 24 hours before study surgery.
  • • Oral direct thrombin inhibitor administration within 3 days before study surgery.
  • • Vitamin K antagonists within 5 days before study surgery.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Basingstoke and North Hampshire Hospital

Basingstoke, United Kingdom, RG24 9NA

Actively Recruiting

Loading map...

Research Team

T

Trial Registration Coordinator

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here